Mizuho analyst Salim Syed keeps a Buy rating on Biogen with a $340 price target after the FDA granted traditional approval to Leqembi. The overall updated label reads generally as expected with no new major surprises, just some additional emphasis and consideration for certain risk groups, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval
- FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
- Biogen, Eisai win full FDA approval for Alzheimer’s drug Leqembi
- FDA converts Biogen Alzheimer’s treatment to full approval